Clinical trials have helped pediatric ophthalmologists and retina specialists make strides in identifying risk factors and predictive models for retinopathy of prematurity (ROP) as well as treatments, said R.V. Paul Chan, MD.
“Historically, the trial of Cryotherapy for Retinopathy of Prematurity [CRYO-ROP] and Early Treatment in Retinopathy of Prematurity [ETROP] Study have provided much of the data we use to guide the management of ROP,” said Dr. Chan, professor of ophthalmology and director, Pediatric Retina and Retinopathy of Prematurity Service, Illinois Eye and Ear Infirmary at the University of Illinois, Chicago.
“With the advent of ROP predictive models, telemedicine, and anti-vascular endothelial growth factor [VEGF] treatments, the way we are managing it is rapidly evolving,” he added.
Dr. Chan mentioned several trials have analyzed ROP predictive models, including WINROP2, CHOP-ROP, e-ROP, CO-ROP, and i-ROP. Some factors analyzed in these trials have included gestational age, birth weight, weight gain, imaging informatics, and genetic factors.
For the most part, the goal of predictive models is to improve the identification of children at risk for certain categories of ROP and reduce the number of screening examinations, Dr. Chan said.
“Even though the results of these studies are promising, we have to keep in mind that all of these models need to be tested rigorously,” he said. “And currently, none of these models is accepted universally for clinical care.”